Argenx Se (ARGX) Work In Process (2020 - 2024)
Argenx Se's (ARGX) quarterly Work In Process came in at $37.2 million in Q2 2024, down 36.81% YoY from $58.8 million in Q3 2023, and down 21.06% on a QoQ basis from $47.1 million in Q4 2023.
Argenx Se (ARGX) Work In Process (2020 - 2024) Analysis & Trends
Argenx Se (ARGX) has 5 years of Work In Process data on file, last reported at $37.2 million in Q2 2024.
- Quarterly Work In Process fell 36.81% year-over-year to $37.2 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $37.2 million (down 36.81% YoY) and the FY2023 annual result came in at $47.1 million, down 27.6% from the prior year.
- Work In Process retreated to $37.2 million in Q2 2024, from $47.1 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $65.0 million in Q4 2022 to a low of $6.4 million in Q4 2020.
- A 5-year average of $41.2 million and a median of $42.4 million in 2021 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2021 — Work In Process jumped 489.12% — and 2024, when it plunged 36.81%.
- Tracing ARGX's Work In Process over 5 years: stood at $6.4 million in 2020, then jumped by 489.12% to $37.7 million in 2021, then jumped by 72.43% to $65.0 million in 2022, then fell by 27.6% to $47.1 million in 2023, then decreased by 21.06% to $37.2 million in 2024.
- The last three Work In Process figures came in at $37.2 million (Q2 2024), $47.1 million (Q4 2023), and $58.8 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 37.16 Mn |
| Dec 31, 2023 | 47.07 Mn |
| Jun 30, 2023 | 58.81 Mn |
| Dec 31, 2022 | 65.02 Mn |
| Jun 30, 2022 | 59.84 Mn |
| Dec 31, 2021 | 37.71 Mn |
| Jun 30, 2021 | 17.99 Mn |
| Dec 31, 2020 | 6.40 Mn |